The anthracycline-trastuzumab interaction: Up-regulated binding may provide vital mechanistic insight
Author:
- Michael S. EwerMEMichael S. Ewer
- 30 September 2007
- journal article
- editorial
- Published by Elsevier in European Journal of Cancer
- Vol. 43 (14) , 2024-2025
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant TrialJournal of Clinical Oncology, 2007
- 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicityEuropean Journal of Cancer, 2007
- Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation–contraction coupling and reduces oxidative stress in adult rat cardiomyocytesJournal of Molecular and Cellular Cardiology, 2006
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New EntityJournal of Clinical Oncology, 2005
- Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancerThe Breast, 2004
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Trastuzumab in the Treatment of Metastatic Breast CancerCirculation, 2000